Cannabis in painful HIV-associated sensory neuropathy: A randomized placebo-controlled trial

Neurology

Volumn 68, Issue 7, 2007, Pages 515-521

  Abrams, D I ^a,b   Jay, C A ^a,c   Shade, S B ^a,b   Vizoso, H ^a,b   Reda, H ^c   Press, S ^c   Kelly, M E ^a,b   Rowbotham, M C ^c   Petersen, K L ^c  

^a SAN FRANCISCO GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID; CANNABIS; CAPSAICIN; LORAZEPAM; PLACEBO; TETRAHYDROCANNABINOL;

ADULT; ANALGESIC ACTIVITY; ANXIETY; ARTICLE; CHRONIC PAIN; CIGARETTE SMOKING; CLINICAL ARTICLE; CLINICAL RESEARCH; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISORIENTATION; DIZZINESS; DRUG EFFECT; DYSPHORIA; EXPERIMENTAL MODEL; FEMALE; HOSPITAL PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERALGESIA; MALE; NAUSEA; NEUROPATHIC PAIN; NOCICEPTIVE STIMULATION; PAIN ASSESSMENT; PARANOIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEDATION; SENSITIZATION; SENSORY NEUROPATHY; SIDE EFFECT; STIMULUS RESPONSE; THERMAL STIMULATION;

AFFECT; CANNABIS; FEMALE; HEAT; HIV INFECTIONS; HUMANS; HYPERALGESIA; MALE; MIDDLE AGED; PAIN; PALLIATIVE CARE; PERIPHERAL NERVOUS SYSTEM DISEASES; PHYSICAL STIMULATION; PHYTOTHERAPY; SENSATION DISORDERS; SMOKING;

EID: 33847013770     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000253187.66183.9c     Document Type: Article

References (44)

1. So YT, Holtzman DM, Abrams DI, Olney RK. Peripheral neuropathy associated with acquired immunodeficiency syndrome. Arch Neurol 1988;45:945-948.
2. Sacktor N. The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active retroviral therapy. J Neurovirol 2002;8(suppl 2):115-121.
3. McArthur JC, Brew BJ, Nath A. Neurological complications of HIV infection. Lancet Neurol 2005;4:543-555.
4. Simpson DM, McArthur JC, Olney R, et al. Lamotrigine for HIV-associated painful sensory neuropathies: a placebo-controlled trial. Neurology 2003;60:1508-1514.
5. Hahn K, Arendt G, Braun JS. A placebo-controlled trial of gabapentin for painful HIV-associated sensory neuropathies. J Neurol 2004;251:1260-1266.
6. Hugen PW, Burger DM, Brinkman K, et al. Carbamazepine-indinavir interaction causes antiretroviral therapy failure. Ann Pharmacother 2000;34:465-470.
7. Simpson DM, Dorfman D, Olney RK, et al. Peptide T in the treatment of painful distal neuropathy associated with AIDS: results of a placebo-controlled trial. Neurology 1996;47:1254-1259.
8. Kemper CA, Kent G, Burton S, Deresinski SC. Mexiletine for HIV-infected patients with painful peripheral neuropathy: a double-blind, placebo-controlled, crossover treatment trial. J Acquir Immune Defic Syndr Hum Retrovirol 1998;19:367-372.
9. Keiburtz K, Simpson D, Yiannoutsos C, et al. A randomized trial of amitriptyline and mexiletine for painful neuropathy in HIV infection. Neurology 1998;51:1682-1688.
10. Shlay JC, Chaloner K, Max MG, et al. Acupuncture and amitriptyline for pain due to HIV-related peripheral neuropathy: a randomized clinical trial. JAMA 1998;280:1590-1595.
11. Paice JA, Ferrans CE, Lashley FR, Shott S, Vizgirda V, Pitrak D. Topical capsaicin in the management of HIV-associated peripheral neuropathy. J Pain Symptom Manage 2000;19:45-52.
12. Calignano A, LaRana G, Giuffrida A, Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature 1998;394:277-281.
13. Walker JM, Huang SM. Cannabinoid analgesia. Pharmacol Ther 2002;95:127-135.
14. Petersen KL, Maloney A, Hoke F, Dahl JB, Rowbotham MC. A randomized study of the effect of oral lamotrigine and hydromorphone on pain and hyperalgesia following heat/capsaicin sensitization. J Pain 2003;4:400-406.
15. Petersen KL, Rowbotham MC. A new human experimental pain model: the heat/capsaicin sensitization model. Neuroreport 1999;10:1511-1516.
16. Foltin RW, Fischman MW, Byrne MF. Effects of smoked cannabis on food intake and body weight of humans living in a residential laboratory. Appetite 1988;25:577-582.
17. Petersen KL, Jones B, Segredo V, Dahl JB, Rowbotham MC. Effect of remifentanil on pain and secondary hyperalgesia associated with the heat-capsaicin sensitization model in healthy volunteers. Anesthesiology 2001;94:15-20.
18. Dirks J, Petersen KL, Rowbotham MC, Dahl JB. Gabapentin suppresses cutaneous hyperalgesia following heat/capsaicin sensitization. Anesthesiology 2002;97:102-107.
19. Dirks K, Petersen KL, Dahl JB. The heat capsaicin sensitization model: a methodological study. J Pain 2003;4:122-128.
20. McNair DM, Lorr M, Droppleman LF. Manual for the Profile of Mood States (POMS). San Diego: Educational and Industrial Testing Service, 1971.
21. NIH Division of AIDS Table for Grading Severity of Adult Adverse Experiences, August 1992. Available at: http://rcc.tech-res-intl.com/tox_tables. htm. Accessed March 6, 2006.
22. Jay C, Shade S, Vizoso H, et al. The effect of smoked cannabis on chronic neuropathic and experimentally-induced pain in HIV neuropathy: results of an open-label pilot study. 11th Conference on Retroviruses and Opportunistic Infections 2004: abstract 496:243.
23. Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001;94:149-158.
24. Finnerup NB, Otto M, McQuay HJ, Jensen TS, Sindrup SH. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 2005;118:289-305.
25. Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 1998;280:1837-1842.
26. Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 1998;280:1831-1836.
27. Rowbotham MC, Twilling L, Davies PS, Reisner L, Taylor K, Mohr D. Oral opioid therapy for chronic peripheral and central neuropathic pain. N Engl J Med 2003;348:1223-1232.
28. Eisenberg E, McNichol ED, Carr DB. Efficacy and safety of opioid agonists in the treatment of neuropathic pain of nonmalignant origin: Systematic review and meta-analysis of randomized controlled trials. JAMA 2005;293:3043-3052.
29. Grunfeld Y, Edery H. Psychopharmacological activity of the active constituents of hashish and some related cannabinoids. Psychopharmacologia 1969;14:200-210.
30. Buxbaum DM. Analgesic activity of 9 -tetrahydrocannabinol in the rat and mouse. Psychopharmacologia 1972;25:275-280.
31. Chesher GB, Dahl CJ, Everingham M, Jackson DM, Marchant-Williams H, Starmer GA. The effect of cannabinoids on intestinal motility and their antinociceptive effect in mice. Br J Pharmacol 1973;49:588-594.
32. Sofia RD, Vassar HB, Nalepa SD. Correlations between pathological changes in the hind paws of rats with adjuvant arthritis and their response to anti-inflammatory and analgesic drugs. Eur J Pharmacol 1973;24:108-112.
33. Moss DE, Johnson RL. Tonic analgesic effects of delta 9-tetrahydrocannabinol as measured with the formalin test. Eur J Pharmacol 1980;61:313-315.
34. Li J, Daughters RS, Bullis C, et al. The cannabinoid receptor agonist WIN 55,212-2 mesylate blocks the development of hyperalgesia produced by capsaicin in rats. Pain 1999;81:25-33.
35. Herzberg U, Eliav E, Bennett GJ, Kopin IJ. The analgesic effect of R(-+)-WIN 55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain. Neurosci Lett 1997;221:157-160.
36. Milstein SL, MacCannell K, Karr G, Clark S. Cannabis-produced changes in pain tolerance. Experienced and non-experienced subjects. Int Pharmacopsychiatry 1975;10:177-182.
37. Noyes R Jr, Baram DA. Cannabis analgesia. Compr Psychiatry 1974;15:531-535.
38. Noyes R, Brunk S, Avery D, Canter A. The analgesic properties of delta-9-tertrahydrocannabinol and codeine. Clin Pharmacol Ther 1975;18:84-89.
39. Svendsen KB, Jensen TS, Back FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ 2004;329:253-260.
40. Rog DJ, Nurmikko TJ, Fride T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005;65:812-819.
41. Joy J, Watson S, Bensen J. Cannabis and medicine: assessing the science base. Washington, DC: National Academy Press; 1999. Available at: http://www.nap.edu
42. Attal N, Brasseur L, Guirimand D, Clermond-Gnamien S, Atlamis S, Bouhassira D. Are oral cannabinoids safe and effective in refractory neuropathic pain? Eur J Pain 2004;8:173-177.
43. Woolridge E, Barton S, Samuel J, Osorio J, Dougherty A, Holdcroft A. Cannabis use in HIV for pain and other medical symptoms. J Pain Symptom Manage 2005;29:358-367.
44. Abrams DI, Hilton JF, Leiser RJ, et al. Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial Ann Intern Med 2003;139:258-299.